Psychopharmacology

, Volume 231, Issue 18, pp 3757–3764

Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients

Authors

  • Matea Nikolac Perkovic
    • Division of Molecular MedicineRudjer Boskovic Institute
  • Gordana Nedic Erjavec
    • Division of Molecular MedicineRudjer Boskovic Institute
  • Maja Zivkovic
    • Department of General PsychiatryClinics for Psychiatry Vrapce
  • Marina Sagud
    • University Hospital Center ZagrebUniversity of Zagreb School of Medicine
  • Suzana Uzun
    • Department of General PsychiatryClinics for Psychiatry Vrapce
  • Alma Mihaljevic-Peles
    • University Hospital Center ZagrebUniversity of Zagreb School of Medicine
  • Oliver Kozumplik
    • Department of General PsychiatryClinics for Psychiatry Vrapce
  • Dorotea Muck-Seler
    • Division of Molecular MedicineRudjer Boskovic Institute
    • Division of Molecular MedicineRudjer Boskovic Institute
Original Investigation

DOI: 10.1007/s00213-014-3515-4

Cite this article as:
Nikolac Perkovic, M., Nedic Erjavec, G., Zivkovic, M. et al. Psychopharmacology (2014) 231: 3757. doi:10.1007/s00213-014-3515-4

Abstract

Rationale

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several neurotransmitter systems including the dopaminergic system. There are mixed reports about the association between the BDNF Val66Met polymorphism, schizophrenia, and treatment response to antipsychotic drugs.

Objectives

The present study evaluated the association of the BDNF Val66Met polymorphism with treatment response to atypical antipsychotic olanzapine in schizophrenia and the possible predictive value of the BDNF Val66Met genotype status in treatment response to antipsychotic medication.

Methods

The study included 590 ethnically homogenous Caucasian patients with schizophrenia (diagnosed using the SCID), 40.2 ± 12.0 years old, treated with olanzapine monotherapy (10–20 mg/day), or with other antipsychotics such as risperidone (3–6 mg/day), clozapine (100–500 mg/day), haloperidol (3–115 mg/day), fluphenazine (4–25 mg/day), and quetiapine (50–800 mg/day). Patients were subdivided into responders and non-responders according to a 50 % reduction in the Positive and Negative Syndrome Scale (PANSS) total and subscale scores after 8 weeks of treatment.

Results

The results, corrected for possible effects of gender and age, showed a significant association between the BDNF Val66Met polymorphism and treatment response to olanzapine in patients. The Val/Val genotype was observed more frequently in treatment responders to olanzapine, and this genotype was associated with an improvement in clinical symptoms.

Conclusions

Our results suggest that BDNF Val66Met variants might influence the response to 8 weeks of monotherapy with olanzapine, in a relatively large sample of patients with schizophrenia.

Keywords

Antipsychotics Olanzapine Risperidone Clozapine Haloperidol Fluphenazine Quetiapine BDNF Val66Met polymorphism Schizophrenia Treatment response

Supplementary material

213_2014_3515_MOESM1_ESM.doc (28 kb)
Supplementary Table S1 (DOC 28 kb)
213_2014_3515_MOESM2_ESM.doc (36 kb)
Supplementary Table S2 (DOC 36 kb)
213_2014_3515_MOESM3_ESM.doc (44 kb)
Supplementary Table S3 (DOC 44 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2014